< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
No significant interference observed with available related molecules.
The Quantikine Human Butyrylcholinesterase/BCHE Immunoassay is a 4.5 hour solid phase ELISA designed to measure BCHE levels in cell culture supernates, cell lysates, tissue lysates, serum, plasma, saliva, urine, and human milk. It contains CHO cell-expressed recombinant human BCHE and antibodies raised against the recombinant protein. Results obtained for naturally occurring human BCHE showed linear curves that were parallel to the standard curves obtained using the Quantikine Human BCHE Immunoassay standards. These results indicate that this kit can be used to determine relative mass values for natural human BCHE.
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
The recovery of human BCHE spiked to levels throughout the range of the assay in various matrices was evaluated.
Average % Recovery
Cell Culture Media (n=4)
Cell Lysis Buffer 1 (n=2)
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of human BCHE were diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Butyrylcholinesterase (BCHE) is a major acetylcholine hydrolyzing enzyme in the circulation. Although it is present in significant amounts (~3 mg/L) in human plasma, no endogenous physiological substrate has been described for this enzyme. It can degrade a large number of ester-containing compounds in addition to acylcholines. Thus, it is likely to play significant pharmacological and toxicological roles. It is thought to be involved in the pathological process of Alzheimer's disease (AD) by depleting acetylcholine. In contrast to ACHE, it attenuates amyloid fibril formation in vitro. BCHE inhibitors have been used to delay symptoms of AD patients by virtue of their ability to enhance acetylcholine availability. Its involvement in a cholinergic anti-inflammatory pathway connect BCHE and ACHE with a possible marker of low-grade systemic inflammation observed in Type-2 diabetes, obesity, hypertension, coronary heart disease, and AD. BCHE can exist in monomeric and multimeric forms. The expressed recombinant mouse BCHE contains multiple forms that consist of soluble monomers, dimers, and tetramers.